Comparative Pharmacology
Head-to-head clinical analysis: TOLMETIN SODIUM versus VOLTAREN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOLMETIN SODIUM versus VOLTAREN XR.
TOLMETIN SODIUM vs VOLTAREN-XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It has anti-inflammatory, analgesic, and antipyretic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
400 mg orally three times daily; maximum 1800 mg/day.
100 mg orally once daily, extended-release formulation. Maximum 150 mg/day (divided as 75 mg twice daily or 100 mg once daily).
None Documented
None Documented
Terminal elimination half-life is approximately 4.5–6 hours (mean 5 hours); may be prolonged in elderly or patients with renal impairment
The terminal elimination half-life is approximately 2 hours. The extended-release formulation (XR) does not alter the half-life; it maintains prolonged therapeutic plasma concentrations with twice-daily dosing.
Renal excretion (~90% as unchanged drug and conjugates), with fecal excretion (~10% as metabolites)
Approximately 65% of a dose is excreted renally as unchanged drug and metabolites (primarily as glucuronide conjugates); about 35% is eliminated via bile in feces.
Category D/X
Category C
NSAID
NSAID